KR870004009A - 티아졸 유도체의 제조방법 - Google Patents

티아졸 유도체의 제조방법 Download PDF

Info

Publication number
KR870004009A
KR870004009A KR1019860008678A KR860008678A KR870004009A KR 870004009 A KR870004009 A KR 870004009A KR 1019860008678 A KR1019860008678 A KR 1019860008678A KR 860008678 A KR860008678 A KR 860008678A KR 870004009 A KR870004009 A KR 870004009A
Authority
KR
South Korea
Prior art keywords
group
carbon atoms
formula
lower alkoxy
alkyl group
Prior art date
Application number
KR1019860008678A
Other languages
English (en)
Other versions
KR930006285B1 (ko
Inventor
요시오 하야시
토메이 오구리
마사키 시노다
미키오 쓰쓰이
카즈오 타카하시
히로시 마이다
Original Assignee
스즈끼 사부로
미쓰비시카구코오교오 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 스즈끼 사부로, 미쓰비시카구코오교오 가부시끼가이샤 filed Critical 스즈끼 사부로
Publication of KR870004009A publication Critical patent/KR870004009A/ko
Application granted granted Critical
Publication of KR930006285B1 publication Critical patent/KR930006285B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2

Abstract

내용 없음

Description

티아졸 유도체의 제조방법
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (2)

  1. 일반식(Ⅵ)의 벤젠유도체를 일반식(Ⅶ)의 카복실산 에스테르와 반응시켜 일반식(Im)의 화합물을 수득한 다음, Z가 X인 경우에는 가수분해를 행하여 산 또는 염을 수득하고, Z와 R13이 함께인 경우에는 필요하다면 에스테르화를 행함을 특징으로 하여 일반식(Ⅰ)의 티아졸 유도체 또는 약학적으로 허용할 수 있는 이의 염을 제조하는 방법.
    상기식에서, R1및 R3는 서로 독립적으로 수소원자, 탄소수 1 내지 8의 알킬그룹, 저급 알콕시카보닐그룹 또는 치환되거나 비치환된 페닐그룹이거나, 이들은 함께 축합 사이클로헥산환에 상당하는 테라메틸렌그룹 또는 축합 벤젠환에 상당하는 비치환되거나 할로겐 원자, 저급 알콕시그룹, 저급 알콕시카보닐그룹 또는 탄소수 1 내지 3의 알킬그룹으로 치환된 부라디에닐렌 그룹이고, R3, R4, R5및 R6는 서로 독립적으로 수소원자, 하이드록실그룹, 저급 알콕시그룹, 탄소수 1 내지 3의 알킬그룹 또는 할로겐원자이며, A는 쇄원(chain member)2 내지 4의 연결그룹이고, B는 쇄원 2 내지 5의 연결그룹이며, Y 는 산소 또는 NH이고, Q는 카복실그룹, 저급알콕시그룹, 하이드록실그룹, 탄소수 2 내지 6의 알콕시카보닐그룹 또는 5-테트라졸릴그룹이며, B5는 직접결합 또는 쇄원 1 내지 4의 연결그룹이고, R13은 탄소수 1 내지 5의 알킬그룹이며, Z는 X 또는 -COX(여기서, X는 할로겐이며, Z와 R13이 함께이어도 상관없다)이다 [단, Y가 산소인 경우, Z 는 X이다].
  2. 일반식(Ⅳ)의 벤즈알데하이드 유도체를 일반식(Ⅴ)의 2-메틸티아졸과 반응시켜 일반식(Ⅰj)의 화합물을 수득한 다음, 필요하다면 가수분해를 행하여 산 또는 염을 수득함을 특징으로 하여 일반식(Ⅰ)의 티아졸 유도체 및 약학적으로 허용할 수 있는 이의 염을 제조하는 방법.
    상기식에서, R1및 R2는 서로 독립적으로 수소원자, 탄소수 1 내지 8의 알킬그룹, 저급 알콕시카보닐그룹 또는 치환되거나 비치환된 페닐그룹이거나, 이들은 함께 축합 사이클로헥산환에 상당하는 테트라메틸렌그룹 또는 축합 벤젠환에 상당하는 비치환되거나 할로겐원자, 저급알콕시그룹, 저급알콕시카보닐 그룹 또는 탄소수 1 내지 3의 알킬그룹으로 치환된 부라디에닐렌 그룹이고, R3, R4, R5은 R6은 서로 독립적으로 수소원자, 하이드록실그룹, 저급 알콕시그룹, 탄소수 1 내지 3의 알킬그룹 또는 할로겐원자이며, R13은 탄소수 1 내지 5의 알콕시그룹이고, B는 쇄원 2 내지 5의 연결그룹이며, Q는 카복실그룹, 저급알콕시그룹, 하이드록실그룹, 탄소수 2 내지 6의 알콕시카보닐그룹 또는 5-테트졸릴 그룹이다.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019860008678A 1985-10-16 1986-10-16 티아졸 유도체의 제조방법 KR930006285B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP228912 1985-10-16
JP60-228912 1985-10-16
JP60228912A JPS62142168A (ja) 1985-10-16 1985-10-16 チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤

Publications (2)

Publication Number Publication Date
KR870004009A true KR870004009A (ko) 1987-05-06
KR930006285B1 KR930006285B1 (ko) 1993-07-12

Family

ID=16883798

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019860008678A KR930006285B1 (ko) 1985-10-16 1986-10-16 티아졸 유도체의 제조방법

Country Status (11)

Country Link
US (1) US4902700A (ko)
EP (1) EP0219436B1 (ko)
JP (1) JPS62142168A (ko)
KR (1) KR930006285B1 (ko)
AU (1) AU603343B2 (ko)
CA (1) CA1326034C (ko)
DE (1) DE3689436T2 (ko)
DK (1) DK169128B1 (ko)
HU (1) HU203228B (ko)
SU (1) SU1554763A3 (ko)
UA (1) UA5585A1 (ko)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5258395A (en) * 1984-11-12 1993-11-02 Yamanouchi Pharmaceutical Co., Ltd. Thiazole compounds as inhibitors of SRS-A
JPS63258854A (ja) * 1987-04-16 1988-10-26 Mitsubishi Kasei Corp カルボキシスチレン誘導体およびそれを有効成分とする薬剤
US4826990A (en) * 1987-09-30 1989-05-02 American Home Products Corporation 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US4895953A (en) * 1987-09-30 1990-01-23 American Home Products Corporation 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents
US5037840A (en) * 1987-11-25 1991-08-06 Merck Frosst Canada, Inc. Benzothiazoles
EP0318085A3 (en) * 1987-11-25 1990-03-14 Merck Frosst Canada Inc. Heterazole dialkanoic acids
CA1322005C (en) * 1987-11-25 1993-09-07 Robert N. Young Benzoheterazoles
US4962117A (en) * 1987-11-25 1990-10-09 Merck Frosst Canada, Inc. Heterazole dialkanoic acids
US5004743A (en) * 1987-11-25 1991-04-02 Merck Frosst Canada, Inc. Pyridyl styrene dialkanoic acids as anti-leukotriene agents
ZA894913B (en) * 1988-07-12 1990-03-28 Ici Pharma Heterocyclic compounds
EP0355353B1 (en) * 1988-07-15 1994-03-16 F. Hoffmann-La Roche Ag Cycloalkylthiazole derivatives
US5001140A (en) * 1989-04-17 1991-03-19 Hoffmann-La Roche Inc. Cycloalkylthiazoles
US5045554A (en) * 1988-11-29 1991-09-03 Monsanto Company Substituted thiazoles and their use as fungicides
JPH02169584A (ja) * 1988-12-22 1990-06-29 Mitsubishi Kasei Corp ビニルチアゾール誘導体およびそれを有効成分とする薬剤
US5089495A (en) * 1989-01-30 1992-02-18 Imperial Chemical Industries Plc Heterocyclic thiazole derivatives and pharmaceutical compositions comprising said derivatives
WO1990011278A1 (en) * 1989-03-24 1990-10-04 The Green Cross Corporation Thiazole compounds and applications thereof
JPH03173874A (ja) * 1989-09-29 1991-07-29 Mitsubishi Kasei Corp 新規複素環化合物
WO1992000963A1 (en) * 1990-07-12 1992-01-23 Yoshitomi Pharmaceutical Industries, Ltd. Styryl compounds and use thereof as medicine
JP2832923B2 (ja) * 1990-07-13 1998-12-09 吉富製薬株式会社 スチリル化合物およびその医薬用途
JP2600644B2 (ja) * 1991-08-16 1997-04-16 藤沢薬品工業株式会社 チアゾリルベンゾフラン誘導体
AU3884893A (en) * 1992-04-10 1993-11-18 Merck Frosst Canada Inc. Thiazole-substituted benzyl alcohols as leukotriene antagonists
AU3884993A (en) * 1992-04-10 1993-11-18 Merck Frosst Canada Inc. Benzothiazole-substituted benzyl alcohols as leukotriene antagonists
DE4219765A1 (de) * 1992-06-17 1993-12-23 Bayer Ag Substituierte (Benzothiazolyl- und Chinoxalyl-methoxy)phenylessigsäurederivate
US5273986A (en) * 1992-07-02 1993-12-28 Hoffmann-La Roche Inc. Cycloalkylthiazoles
US5508408A (en) * 1993-09-10 1996-04-16 Ciba-Geigy Corporation Quinoline compound
WO1996033181A1 (en) * 1995-04-21 1996-10-24 Daiichi Pharmaceutical Co., Ltd. Ethynylthiazole derivative
WO1997021691A1 (fr) * 1995-12-14 1997-06-19 Kaken Pharmaceutical Co., Ltd. Derives thiazole
US6376671B1 (en) 1997-06-17 2002-04-23 Kaken Pharmaceutical Co., Ltd. 2-sulfamoylbenzoic acid derivatives
JP2004137284A (ja) * 1997-06-17 2004-05-13 Kaken Pharmaceut Co Ltd ２−スルファモイル安息香酸誘導体
AU732106B2 (en) * 1997-06-17 2001-04-12 Kaken Pharmaceutical Co., Ltd. 2-sulfamoylbenzoic acid derivatives
US6083966A (en) * 1998-08-31 2000-07-04 University Of Florida Thiazoline acid derivatives
EP1143951A3 (en) * 1998-09-21 2002-02-06 University Of Florida Research Foundation, Inc. Antimalarial agents
EP1214303A1 (en) * 1999-08-31 2002-06-19 Merck & Co., Inc. Heterocyclic compounds and methods of use thereof
DE50009208D1 (de) 1999-11-25 2005-02-17 Ciba Sc Holding Ag Hydroxyphenylvinylthiazole
EP1103180B1 (de) * 1999-11-25 2005-01-12 Ciba SC Holding AG Hydroxyphenylvinylthiazole
JPWO2002087589A1 (ja) * 2001-04-26 2004-08-12 第一製薬株式会社 薬剤排出ポンプ阻害薬
US7056917B2 (en) 2001-04-26 2006-06-06 Daiichi Pharmaceutical Co., Ltd. Drug efflux pump inhibitor
SE0102299D0 (sv) 2001-06-26 2001-06-26 Astrazeneca Ab Compounds
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
GB0226930D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
BRPI0410348A (pt) 2003-05-14 2006-05-30 Torreypines Therapeutics Inc compostos e usos dos mesmos na modulação de amilóide-beta
WO2005034949A1 (en) * 2003-09-09 2005-04-21 University Of Florida Desferrithiocin derivatives and their use as iron chelators
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
EP1802570A1 (en) 2004-10-16 2007-07-04 AstraZeneca AB Process for making phenoxy benzamide compounds
ES2732625T3 (es) 2005-04-04 2019-11-25 Univ Florida Análogos de poliéter de desferritiocina
TW200714597A (en) 2005-05-27 2007-04-16 Astrazeneca Ab Chemical compounds
AU2006268406C1 (en) 2005-07-09 2011-02-24 Astrazeneca Ab Heteroaryl benzamide derivatives for use as GLK activators in the treatment of diabetes
TW200738621A (en) 2005-11-28 2007-10-16 Astrazeneca Ab Chemical process
JP4836704B2 (ja) * 2006-08-07 2011-12-14 中国電力株式会社 端子台用保護カバー
TW200825063A (en) 2006-10-23 2008-06-16 Astrazeneca Ab Chemical compounds
SA07280576B1 (ar) 2006-10-26 2011-06-22 استرازينيكا ايه بي مركبات بنزويل أمينو سيكليل غير متجانسة بأعتبارها عوامل منشطة للجلوكوكيناز
EP2121666A1 (en) 2006-12-21 2009-11-25 AstraZeneca AB Novel crystalline compound useful as glk activator
AU2008229472B2 (en) 2007-03-15 2013-03-14 University Of Florida Research Foundation, Inc. Desferrithiocin polyether analogues
PE20110568A1 (es) 2008-08-04 2011-09-07 Astrazeneca Ab Agentes terapeuticos 414
EP2166006A1 (en) * 2008-09-18 2010-03-24 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
GB0902406D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Crystalline polymorphic form
GB0902434D0 (en) 2009-02-13 2009-04-01 Astrazeneca Ab Chemical process
AR076221A1 (es) * 2009-04-09 2011-05-26 Astrazeneca Ab Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
AR076220A1 (es) 2009-04-09 2011-05-26 Astrazeneca Ab Derivados de pirazol [4,5 - e] pirimidina
KR101907535B1 (ko) 2009-10-02 2018-10-15 아벡신 에이에스 소염제 2-옥소티아졸 및 2-옥소옥사졸
CN113398126A (zh) 2011-12-16 2021-09-17 佛罗里达大学研究基金会 4′-去铁硫素类似物的用途
WO2014118195A1 (en) 2013-01-29 2014-08-07 Avexxin As Antiinflammatory and antitumor 2-oxothiazoles and 2-oxothiophenes compounds
AU2014352780A1 (en) 2013-11-22 2016-06-09 University Of Florida Research Foundation, Inc. Desferrithiocin analogs and uses thereof
GB201413695D0 (en) 2014-08-01 2014-09-17 Avexxin As Compound
US10570104B2 (en) 2015-04-27 2020-02-25 University Of Florida Research Foundation, Incorporated Metabolically programmed metal chelators and uses thereof
GB201604318D0 (en) 2016-03-14 2016-04-27 Avexxin As Combination therapy
US11919873B1 (en) 2023-08-29 2024-03-05 King Faisal University 1,3-benzothiazol-2-yl-N′-(benzoyloxy)ethanimidamide as an antitumor and antimicrobial compound
US11912676B1 (en) 2023-08-29 2024-02-27 King Faisal University N'-[(4-chlorobenzoyl)oxy]-1,3-benzothiazole-2-carboximidamide as an antitumor and antimicrobial compound

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3137655A (en) * 1961-03-21 1964-06-16 Glanzstoff Ag Optical brightening
DE1670908A1 (de) * 1967-08-16 1971-04-29 Hoechst Ag Neue Benzimidazolverbindungen,Verfahren zu ihrer Herstellung und ihre Verwendung als optische Aufhellungsmittel
US3974282A (en) * 1972-11-04 1976-08-10 Beecham Group Limited Hypoglycemic stilbazolte derivatives
DE2331444A1 (de) * 1973-06-20 1975-01-23 Hoechst Ag Neue styryl-benzoxazole, verfahren zu deren herstellung und ihre verwendung als optische aufhellungsmittel
DE3148291A1 (de) * 1981-12-05 1983-06-09 Basf Ag, 6700 Ludwigshafen Harnstoffderivate, verfahren zu ihrer herstellung und ihre verwendung zur bekaempfung unerwuenschten pflanzenwuchses
US4594425A (en) * 1984-02-09 1986-06-10 American Home Products Corporation Heterocyclic compounds as antiallergic agents
US4581457A (en) * 1984-09-21 1986-04-08 American Home Products Corporation Heterocyclic sulfonamides

Also Published As

Publication number Publication date
AU6393086A (en) 1987-04-30
UA5585A1 (uk) 1994-12-28
JPH057386B2 (ko) 1993-01-28
DE3689436T2 (de) 1994-04-14
CA1326034C (en) 1994-01-11
EP0219436B1 (en) 1993-12-22
DK169128B1 (da) 1994-08-22
JPS62142168A (ja) 1987-06-25
EP0219436A3 (en) 1989-12-27
HU203228B (en) 1991-06-28
DK494186A (da) 1987-04-17
SU1554763A3 (ru) 1990-03-30
DK494186D0 (da) 1986-10-15
US4902700A (en) 1990-02-20
HUT47090A (en) 1989-01-30
KR930006285B1 (ko) 1993-07-12
AU603343B2 (en) 1990-11-15
DE3689436D1 (de) 1994-02-03
EP0219436A2 (en) 1987-04-22

Similar Documents

Publication Publication Date Title
KR870004009A (ko) 티아졸 유도체의 제조방법
KR840003260A (ko) [(3-아미노-3-카르복시)-프로필-1]포스핀산 유도체의 제조법
KR840004080A (ko) 살리실산 유도체의 제조방법
KR860002450A (ko) 아미노-알콜유도체의 제조방법
KR840005723A (ko) 티아졸유도체의 제조방법
KR860001102A (ko) 디히드로오로트산 유도체의 제조방법
EP0342599A3 (en) Polyacetyl oligosaccharide derivatives
KR880000377A (ko) 트란스 헥사하이드로 테레프탈산 에스테르 유도체의 제조방법
KR860004051A (ko) 치환된 페닐피페라진 유도체의 제조방법
KR850006004A (ko) [(1,3-디 옥소-1,3-프로판디일)디이미노)]비스벤 조산 유도체의 제조방법
KR830006293A (ko) 신규 폴리아자 헤테로고리 화합물의 제조방법
KR840000505A (ko) N- 페닐피라졸유도체의 제조방법
KR860006461A (ko) 항알레르기 작용을 갖는 화합물의 제조방법
KR890012968A (ko) 치환 니코틴산 에스테르의 제조법
KR880000384A (ko) 안식향산 유도체의 제조방법
KR850007247A (ko) 바이페닐릴설포닐 우레아의 제조방법
KR850004086A (ko) 플루오렌 유도체의 제조방법
KR850008493A (ko) N-포르밀-디티오포스폰산 아미드의 제조방법
KR890002176A (ko) 신규한 세펨 화합물
KR890014504A (ko) 4-(2'-시아노 에틸티오)메틸-2-구아니디노티아졸의 제조방법
KR860000347A (ko) 벤조퀴논 유도체의 제조방법
KR860009006A (ko) 2-티오크로메닐리덴아세토아세트산 에스테르의 제조방법
KR840004055A (ko) 진통 및 소염의 효능을 갖는 화합믈의 제조방법
KR840001554A (ko) 벤즈아미드 유도체의 제법
KR890002178A (ko) 신규한 세펨 화합물

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 19980709

Year of fee payment: 6

LAPS Lapse due to unpaid annual fee